静脉注射免疫球蛋白与观察治疗儿童新诊断免疫性血小板减少症的随机对照试验
这项多中心随机对照试验将206例新诊断免疫性血小板减少症患儿(血小板计数≤20×10⁹/L、轻中度出血)随机分为单次静脉注射免疫球蛋白0.8 g/kg组(n=102)与密切观察组(n=104)。慢性免疫性血小板减少症发生率在静脉注射免疫球蛋白组为18.6%、观察组为28.9%(RR 0.64,95%CI 0.38-1.08);12个月时血小板计数<100×10⁹/L者分别为10%与12%(RR 0.83,95%CI 0.38-1.84)。观察组4-5级出血发生率为9%,静脉注射免疫球蛋白组为1%。
要点
- 静脉注射免疫球蛋白组慢性免疫性血小板减少症发生率18.6%,观察组28.9%,RR 0.64(95%CI 0.38-1.08)。
- 12个月时血小板计数<100×10⁹/L者静脉注射免疫球蛋白组10%、观察组12%,RR 0.83(95%CI 0.38-1.84)。
- 观察组4-5级出血发生率为9%,静脉注射免疫球蛋白组为1%。
核心结论
- 静脉注射免疫球蛋白组慢性免疫性血小板减少症发生率低于观察组但未达统计学显著(RR 0.64,95%CI 0.38-1.08)。
- 静脉注射免疫球蛋白组前3个月完全缓解率显著高于观察组。
研究设计与样本
- 多中心随机对照试验,纳入3月龄至16岁新诊断免疫性血小板减少症、血小板计数≤20×10⁹/L、轻中度出血的儿童206例。
- 随机分配至单次静脉注射免疫球蛋白0.8 g/kg组(n=102)或密切观察组(n=104)。
主要发现
- 慢性免疫性血小板减少症(研究启动时定义为6个月后血小板计数<150×10⁹/L)发生率静脉注射免疫球蛋白组18.6% vs 观察组28.9%(RR 0.64,95%CI 0.38-1.08)。
- 12个月时血小板计数<100×10⁹/L(现行慢性免疫性血小板减少症定义)者静脉注射免疫球蛋白组10% vs 观察组12%(RR 0.83,95%CI 0.38-1.84)。
- 前3个月完全缓解率静脉注射免疫球蛋白组显著高于观察组。
- 免疫球蛋白G Fc受体IIb基因变异与两组早期完全缓解相关。
- 4-5级出血发生率观察组9% vs 静脉注射免疫球蛋白组1%。
关键数值与推荐
- 慢性免疫性血小板减少症在研究启动时定义为6个月后血小板计数<150×10⁹/L。
- 现行慢性免疫性血小板减少症定义为12个月时血小板计数<100×10⁹/L。
- 试验注册号:NTR 1563。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of children with newly diagnosed immune thrombocytopenia (ITP) consists of careful observation or immunomodulatory treatment. Observational studies suggest a lower risk for chronic ITP in children after intravenous immunoglobulin (IVIg) treatment. In this multicenter randomized trial, children aged 3 months to 16 years with newly diagnosed ITP, platelet counts 20 × 109/L or less, and mild to moderate bleeding were randomly assigned to receive either a single infusion of 0.8 g/kg IVIg or careful observation. Primary outcome was development of chronic ITP, which at the time of study initiation was defined as a platelet count lower than 150 × 109/L after 6 months. Two hundred six children were allocated to receive IVIg (n = 102) or careful observation (n = 104). Chronic ITP occurred in 18.6% of the patients in the IVIg group and 28.9% in the observation group (relative risk [RR], 0.64; 95% confidence interval [CI], 0.38-1.08). Platelet counts lower than 100 × 109/L at 12 months (current definition of chronic ITP) were observed in 10% of children in the IVIg group and 12% in the observation group (RR, 0.83; 95% CI, 0.38-1.84). Complete response rates in the first 3 months were significantly higher in the IVIg group. Immunoglobulin G Fc receptor IIb genetic variations were associated with early complete response in both groups. Grade 4 to 5 bleeding occurred in 9% of the patients in the observation group vs 1% in the IVIg group. This trial was registered at www.trialregister.nl as NTR 1563.
引用
- Heitink-Pollé KMJ, Uiterwaal CSPM, Porcelijn L, et al. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood. 2018. PMID: 29945954. doi:10.1182/blood-2018-02-830844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。